You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC / CE

Cognitive Function Across the Diagnostic Spectrum: Impact of Exercise, Social Connection, and Positive Life Events

  • Authors: Tristin D. Abair, PhD
  • CME / ABIM MOC / CE Released: 3/16/2023
  • Valid for credit through: 3/16/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    Nurses - 0.25 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)

    IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for psychiatrists, neurologists, nurse practitioners, primary care physicians, physician assistants, nurses, pharmacists, and other healthcare providers who provide care for patients with neuropsychiatric disorders.

The goal of this activity is for learners to be better able to recognize the transdiagnostic issues with cognitive function and increase their knowledge regarding impact of exercise, social connection, and positive life events.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Role of cognitive function across the diagnostic spectrum
    • Impact of exercise, social connection, and positive life events on neural connectivity
  • Demonstrate greater confidence in their ability to
    • Incorporate interprofessional strategies to improve psychiatric care


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Tristin D. Abair, PhD

    Senior Medical Writer
    Medscape, LLC

    Disclosures

    Tristin D. Abair, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Nurse Planner

  • Amy Bernard, MS, BSN, RN, NPD-BC, CHCP

    Senior Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amy Bernard, MS, BSN, RN, NPD-BC, CHCP has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-099-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Cognitive Function Across the Diagnostic Spectrum: Impact of Exercise, Social Connection, and Positive Life Events

Authors: Tristin D. Abair, PhDFaculty and Disclosures

CME / ABIM MOC / CE Released: 3/16/2023

Valid for credit through: 3/16/2024

processing....

References

  1. Treece C. DSM-III as a research tool. Am J Psychiatry. 1982;139:577-583.
  2. National Institute of Mental Health. Research domain criteria. Accessed March 2, 2023. https://www.nimh.nih.gov/research/research-funded-by-nimh/rdoc/about-rdoc
  3. Millan MJ, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012;11:141-168.
  4. McIntyre RS, et al. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. Compr Psychiatry. 2015;56:279-282.
  5. Thoma N, et al. Contemporary cognitive behavior therapy: a review of theory, history, and evidence. Psychodyn Psychiatry. 2015;43:423-461.
  6. Arnsten AF, et al. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry. 2012;51:356-367.
  7. Bush G, et al. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci. 2000;4:215-222.
  8. Dean J, et al. The neurobiology of depression: an integrated view. Asian J Psychiatr. 2017;27:101-111.
  9. Jiang X, et al. Connectome analysis of functional and structural hemispheric brain networks in major depressive disorder. Transl Psychiatry. 2019;9:136.
  10. Duman RS, et al. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22:238-249.
  11. Fischer AS, et al. Neural markers of resilience in adolescent females at familial risk for major depressive disorder. JAMA Psychiatry. 2018;75:493-502.
  12. Jaeger J. Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing. J Clin Psychopharmacol. 2018;38:513-519.
  13. Baune BT, et al. A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol. 2018;21:97-107.
  14. Mattingly G, et al. The impact of cognitive challenges in major depression: the role of the primary care physician. Postgrad Med. 2016;128:665-671.
  15. Hemager N, et al. Assessment of neurocognitive functions in 7-year-old children at familial high risk for schizophrenia or bipolar disorder: the Danish High Risk and Resilience Study VIA 7. JAMA Psychiatry. 2018;75:844-852.
  16. Remington G, et al. Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. Expert Rev Neurother. 2011;11:589-607.
  17. Osugo M, et al. Dopamine partial agonists and prodopaminergic drugs for schizophrenia: Systematic review and meta-analysis of randomized controlled trials. Neurosci Biobehav Rev. 2022;135:104568.
  18. Harvey PD, et al. Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study. Schizophr Res. 2015;166:334-338.
  19. Brannan SK, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384:717-726.
  20. Pretus C, et al. Stepwise functional connectivity reveals altered sensory-multimodal integration in medication-naïve adults with attention deficit hyperactivity disorder. Hum Brain Mapp. 2019;40:4645-4656.
  21. Wigal T, et al. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010;6:34.
  22. Nasser A, et al. Relationship between the ADHD symptoms, executive function, and Clinical Global Impression rating scale scores in a phase 3 trial of viloxazine extended-release capsules (QelbreeTM) in adults with ADHD. Presented at: Psych Congress 2021; Oct 29-Nov 01, 2021; San Antonio, TX.
  23. Hoang TD, et al. Effect of early adult patterns of physical activity and television viewing on midlife cognitive function. JAMA Psychiatry. 2016;73:73-79.
  24. Ra CK, et al. Association of digital media use with subsequent symptoms of attention-deficit/hyperactivity disorder among adolescents. JAMA. 2018;320:255-263.
  25. Hollis C, et al. Annual research review: digital health interventions for children and young people with mental health problems - a systematic and meta-review. J Child Psychol Psychiatry. 2017;58:474-503.
  26. Kollins SH, et al. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. Lancet Digit Health. 2020;2:e168-e178.
« Return to: Cognitive Function Across the Diagnostic Spectrum: Impact of Exercise, Social Connection, and Positive Life Events
  • Print